Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration
Human Genetics · 2024
DOI: 10.1007/s00439-024-02641-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Genetics, 2024. Verfasst von Zebin Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Xiangya Hospital at Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China. Hauptthemen laut MEDLINE: Cisplatin, Acute Kidney Injury, Ferroptosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Innovative Platform and Talents Project of Hunan Province, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cisplatin-induced acute kidney injury (CP-AKI) is a common complication in cancer patients. Although ferroptosis is believed to contribute to the progression of CP-AKI, its mechanisms remain incompletely understood. In this study, after initially processed individual omics datasets, we integrated multi-omics data to construct a ferroptosis network in the kidney, resulting in the identification of the key driver TACSTD2. In vitro and in vivo results showed that TACSTD2 was notably upregulated in cisplatin-treated kidneys and BUMPT cells. Overexpression of TACSTD2 accelerated ferroptosis, while its gene disruption decelerated ferroptosis, likely mediated by its potential downstream targets HMGB1, IRF6, and LCN2. Drug prediction and molecular docking were further used to propose that drugs targeting TACSTD2 may have therapeutic potential in CP-AKI, such as parthenolide, progesterone, premarin, estradiol and rosiglitazone. Our findings suggest a significant association between ferroptosis and the development of CP-AKI, with TACSTD2 playing a crucial role in modulating ferroptosis, which provides novel perspectives on the pathogenesis and treatment of CP-AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Xiangya Hospital at Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China.
- Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, USA.
- Department of Nephrology, The Second Xiangya Hospital at Central South University, Changsha, Hunan, China.
- Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
- Xiangya Hospital, Central South University, Changsha, Hunan, China. ljch1999@csu.edu.cn.
- The Center of Systems Biology and Data Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China. ljch1999@csu.edu.cn.
Förderung
- Innovative Platform and Talents Project of Hunan Province
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Hunan Province Natural Science Foundation
- Excellent Youth Foundation of Hunan Provincial Natural Science Foundation Committee
Zitieren
APA
Deng, Z., Dong, Z., Wang, Y., Dai, Y., Liu, J., & Deng, F. (2024). Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration. Human Genetics. https://doi.org/10.1007/s00439-024-02641-w
Vancouver
Deng Z, Dong Z, Wang Y, Dai Y, Liu J, Deng F. Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration. Human Genetics. 2024. doi:10.1007/s00439-024-02641-w
BibTeX
@article{Deng2024,
author = {Deng, Zebin and Dong, Zheng and Wang, Yinhuai and Dai, Yingbo and Liu, Jiachen and Deng, Fei},
title = {Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration},
journal = {Human Genetics},
year = {2024},
doi = {10.1007/s00439-024-02641-w}
}
EUVIMED